Articles scientifiques

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Année : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783

Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Auteurs : Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E
Année : 2018
Journal : BMC Cancer
Volume : 18
Pages : 651

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Année : 2018
Journal : JAMA Oncol
Volume : 4
Pages : e181564

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Auteurs : Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart-Gebhart M
Année : 2018
Journal : Cancer Treat Rev
Volume : 67
Pages : 10-20

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

Auteurs : Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, de Azambuja E
Année : 2018
Journal : Expert Rev Anticancer Ther
Volume : 18
Pages : 629-649

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Auteurs : Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard-Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F
Année : 2017
Journal : J Clin Invest
Volume : 127(8)
Pages : 3090-3102

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Auteurs : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Année : 2017
Journal : EMBO Mol Med
Volume : 9
Pages : 1052-1066

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 15759

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Auteurs : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Année : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15

Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.

Auteurs : Yates LR, Desmedt C
Année : 2017
Journal : Clin Cancer Res
Volume : 23
Pages : 2630-2639

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Auteurs : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Année : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 14944

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Auteurs : Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Année : 2017
Journal : J Clin Oncol
Volume : 35
Pages : 1421-1429

Transcriptomic and genomic features of invasive lobular breast cancer.

Auteurs : Desmedt C, Zoppoli G, Sotiriou C, Salgado R
Année : 2017
Journal : Semin Cancer Biol
Volume : 44
Pages : 98-105

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Auteurs : Gingras I, Holmes E, de Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart-Gebhart M, Azim HA Jr
Année : 2017
Journal : J Natl Cancer Inst
Volume : 109

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Auteurs : Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, OMeara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van t Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR
Année : 2017
Journal : Nature
Volume : 543
Pages : 714-718

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Auteurs : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Auteurs : Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, Van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S
Année : 2017
Journal : Nat Med
Volume : 23(4)
Pages : 517-525

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 128-135

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.

Auteurs : Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart-Gebhart M, Paesmans M, Sotiriou C
Année : 2017
Journal : Clin Cancer Res
Volume : 23(11)
Pages : 2702-2712